Research programme: histone deacetylase inhibitors - MethylGene
Alternative Names: MG 4230; MG 4915; MG 5026; Next generation inhibitors; Sirtuin inhibitorsLatest Information Update: 25 Jan 2024
At a glance
- Originator MethylGene
- Class Sirtuins; Small molecules
- Mechanism of Action Histone deacetylase inhibitors; SIRT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Cancer; Diabetes mellitus; Inflammation
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 30 Mar 2010 Preclinical development is ongoing in USA
- 25 Mar 2008 Preclinical development is ongoing